01—Abstract
Summary
Summary of the 8-K/A filed September 9, 2025. Cited figures are marked; the original filing is the authoritative source.
UnitedHealth Group (UNH) has issued an 8-K/A filing to update investors on upcoming meetings with analysts and investors.
The company plans to reaffirm its adjusted 2025 earnings per share (EPS) expectations previously provided on July 29, 2025. Management acknowledged that the recently closed acquisition of Amedisys is expected to be dilutive to adjusted EPS in the near term due to financing costs and integration expenses. Additionally, UNH provided a preliminary outlook for its Medicare Advantage star ratings for Star Year 2026 / Payment Year 2027.
Based on an initial review, the company anticipates approximately 78%a of its membership will be in plans with 4 stars or higher, which is in line with their historical performance and expectations. These meetings will also cover broader topics like company strategy, market positions, and recent results, as previously disclosed.
02—Key points
Key Highlights
- Reaffirmation of previously disclosed adjusted 2025 EPS guidance.
- Amedisys acquisition is expected to be dilutive to adjusted EPS due to financing and integration costs.
- Preliminary estimate of 78% of Medicare Advantage membership in 4-star or higher plans for Star Year 2026 / Payment Year 2027.
- Star ratings are consistent with expectations and historical performance.
- Information shared during investor meetings is not considered officially 'filed' under Section 18 of the Securities Exchange Act of 1934 unless expressly stated.
- Company strategy, market positions, and recent results may also be discussed.
- Extensive list of risk factors are detailed, impacting future results and forward-looking statements.
03—Questions
Frequently Asked Questions
When is UnitedHealth Group expected to reaffirm its 2025 adjusted EPS guidance?
UnitedHealth Group plans to reaffirm its adjusted 2025 earnings per share expectations during investor and analyst meetings scheduled between September 8, 2025, and September 10, 2025. These expectations were initially disclosed on July 29, 2025.
How will the Amedisys acquisition impact UnitedHealth Group's earnings in 2025?
The company anticipates that the Amedisys acquisition, which closed in August 2025, will be dilutive to adjusted earnings per share. This impact is primarily attributed to financing costs associated with the acquisition and integration-related investments.
What are UnitedHealth Group's preliminary Medicare Advantage star ratings for the upcoming year?
Based on a preliminary review, UnitedHealth Group estimates that approximately 78% of its Medicare Advantage membership will be in plans rated 4 stars or higher for Star Year 2026 / Payment Year 2027. This is consistent with their expectations and historical performance, though the data is not yet final.
Is the information provided in this 8-K/A filing considered officially filed with the SEC?
The information disclosed under Item 7.01 (Regulation FD Disclosure) is generally not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated by reference into other SEC filings, unless the Company specifically states otherwise in a future filing.
04—Continue